Clinical trials: Inadequate Response
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Primary Biliary Cholangitis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
- Trial name
- NCT03394924
- Testing
- EDP-305 1 mg, EDP-305 2.5 mg
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 68 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Psoriasis
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy.
- Trial name
- TRANSIT (NCT01059773)
- Testing
- Ustekinumab, Methotrexate
- Where
- 76 sites in Austria, Belgium and 17 more
- Volunteers
- 490 people
- Sponsor
- Janssen-Cilag International NV
Arthritis, Rheumatoid
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
- Trial name
- NCT01554696
- Testing
- peficitinib, methotrexate
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 379 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)
This single-arm, open-label, multicenter study evaluated the safety and tolerability and the efficacy in reducing disease activity of tocilizumab [RoActemra/Actemra] as monotherapy or in combination with methotrexate in patients…
- Trial name
- NCT01063062
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 9 sites in Egypt
- Volunteers
- 107 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 1 (NCT02889796)
- Testing
- Filgotinib, Adalimumab, MTX
- Where
- 230 sites in United States, Argentina and 28 more
- Volunteers
- 1,759 people
- Sponsor
- Gilead Sciences
Major Depressive Disorder
Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
- Trial name
- MADDRE (NCT01397903)
- Where
- 27 sites in Greece
- Volunteers
- 545 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
This single arm study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who are receiving methotrexate treatment, and who have had an inadequate response to one anti-TNF alpha therapy.
- Trial name
- NCT00576433
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 18 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT05198310
- Testing
- KPL-404
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 145 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Rheumatoid Arthritis
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Primary Objective: To demonstrate the treatment effect of sarilumab and methotrexate (MTX) compared to etanercept and MTX in participants with rheumatoid arthritis (RA) and an inadequate response to adalimumab and MTX by…
- Trial name
- RA-COMPARE (NCT01764997)
- Testing
- Sarilumab, Etanercept, Methotrexate
- Where
- 257 sites in United States, Argentina and 29 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
This Phase 2a study is designed to evaluate the safety and tolerability of multiple subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in patients with active rheumatoid arthritis (RA) who have…
- Trial name
- NCT00292422
- Testing
- BG9924
- Where
- 10 sites in United States, Poland
- Volunteers
- 50 people
- Sponsor
- Biogen
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Inflammation, Rheumatoid Arthritis
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This trial is conducted in Europe. The aim of the trial is to investigate the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis (RA) and an inadequate response to…
- Trial name
- NCT02097264
- Testing
- NNC0109-0012, Adalimumab
- Sponsor
- Novo Nordisk A/S
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Rheumatoid Arthritis
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment.
- Trial name
- NCT02006706
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 3 sites in Serbia
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
- Trial name
- NCT02047604
- Testing
- SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bausch Health Americas, Inc.
Rheumatoid Arthritis
A Study in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to…
- Trial name
- RA-BEAM (NCT01710358)
- Testing
- Adalimumab, Baricitinib, Methotrexate
- Where
- 213 sites in United States, Argentina and 26 more
- Volunteers
- 1,307 people
- Sponsor
- Eli Lilly and Company
Acute Decompensated Heart Failure
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05876078
- Testing
- Doraya catheter
- Where
- 10 sites in Germany, Italy and 3 more
- Volunteers
- 25 people
- Sponsor
- Revamp Medical Ltd.
Primary Biliary Cirrhosis (PBC)
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).
- Trial name
- NCT02609048
- Testing
- Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences